Reason for request
Inclusion on the lists of medicines reimbursed by National Health Insurance and approved for hospital use.
Clinical Benefit
| Substantial |
The actual benefit of this proprietary drug is substantial. |
Clinical Added Value
| no clinical added value |
The Transparency Committee considers that 3rd generation VARNOLINE CONTINU does not provide an improvement in actual benefit (IAB V) compared to 2nd generation oral contraceptives. |
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
gQp1RtG8TY71AfEL
